Bioventus (BVS) Stock Forecast & Price Target

Bioventus is supported by a resilient core franchise in hyaluronic acid injections, bone graft substitutes, and fracture care, with Durolane’s growth since its U.S. launch in 2018 reinforcing pricing power and durable payor and clinical advantages. Management’s confidence is backed by strong execution: adjusted EBITDA margins expanded from low teens in 2022 to over 20% in 2025, organic revenue grew 7.5% in FY25, and free cash flow rose to over $72 million in 2025 from less than $38 million in 2024. Its positive outlook also reflects a focused investment plan—about $13 million in 2026, with more than half directed to PNS—aimed at scaling faster-growing businesses while debt falls toward under 2x leverage and capital allocation flexibility improves.

Bioventus is facing a difficult fundamental setup because its growth depends on operating in highly competitive markets where large, well-capitalized rivals such as Johnson & Johnson and Medtronic can pressure share and pricing. Its business is also exposed to costly FDA and global regulatory approvals, reimbursement risk, and limited utilization in markets where governments control procedure pricing, all of which can slow revenue expansion and compress margins. Added acquisition and commercial-network execution risk, plus the sudden 10% CMS reimbursement cut on bone growth stimulator devices, heighten uncertainty around future operating results and cash generation.